NO20081149L - Fremgangsmate for behandling av B-celle-maligniteter ved bruk av TACI-IG fusjonsmolekyl - Google Patents
Fremgangsmate for behandling av B-celle-maligniteter ved bruk av TACI-IG fusjonsmolekylInfo
- Publication number
- NO20081149L NO20081149L NO20081149A NO20081149A NO20081149L NO 20081149 L NO20081149 L NO 20081149L NO 20081149 A NO20081149 A NO 20081149A NO 20081149 A NO20081149 A NO 20081149A NO 20081149 L NO20081149 L NO 20081149L
- Authority
- NO
- Norway
- Prior art keywords
- taci
- fusion molecule
- cell malignancies
- treating
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70691205P | 2005-08-09 | 2005-08-09 | |
PCT/US2006/031277 WO2007019575A2 (en) | 2005-08-09 | 2006-08-09 | Methods for treating b-cell malignancies using taci-ig fusion molecule |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20081149L true NO20081149L (no) | 2008-04-30 |
Family
ID=37672215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20081149A NO20081149L (no) | 2005-08-09 | 2008-03-04 | Fremgangsmate for behandling av B-celle-maligniteter ved bruk av TACI-IG fusjonsmolekyl |
Country Status (15)
Country | Link |
---|---|
US (1) | US7842292B2 (xx) |
EP (1) | EP1922080A2 (xx) |
JP (1) | JP2009507777A (xx) |
KR (1) | KR20080056714A (xx) |
CN (1) | CN101262876A (xx) |
AR (1) | AR059945A1 (xx) |
AU (1) | AU2006278229B2 (xx) |
CA (1) | CA2618765A1 (xx) |
EA (1) | EA016083B1 (xx) |
IL (1) | IL188403A (xx) |
MX (1) | MX2008001661A (xx) |
NO (1) | NO20081149L (xx) |
UA (1) | UA93516C2 (xx) |
WO (1) | WO2007019575A2 (xx) |
ZA (1) | ZA200801354B (xx) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
AR059025A1 (es) | 2005-08-09 | 2008-03-12 | Zymogenetics Inc | Metodos para el tratamiento y prevencion de proliferacion de celulas anormales utilizando moleculas de fusion taci |
AR059945A1 (es) | 2005-08-09 | 2008-05-14 | Zymogenetics Inc | Metodos para tratar afecciones malignas de celulas b que utilizan una molecula de fusion taci-ig |
AR060935A1 (es) | 2006-05-15 | 2008-07-23 | Ares Trading Sa | Metodos para tratar enfermedades autoinmunes utilizando una molecula de fusion taci- ig |
CA2690119A1 (en) * | 2007-06-13 | 2008-12-24 | Ares Trading S.A. | Use of taci-ig fusion protein such as atacicep for the manufacture of a medicament for treating lupus erythematosus |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
WO2011028945A1 (en) * | 2009-09-03 | 2011-03-10 | Genentech, Inc. | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
CN103502472B (zh) | 2011-02-28 | 2017-06-06 | 弗·哈夫曼-拉罗切有限公司 | 生物标记物和用于预测对b‑细胞拮抗剂的响应的方法 |
WO2016003876A1 (en) | 2014-07-03 | 2016-01-07 | Oklahoma Medical Research Foundation | Treatment of multiple sclerosis and neuromyelitis optica |
JP2023525032A (ja) | 2020-05-08 | 2023-06-14 | アルパイン イミューン サイエンシズ インコーポレイテッド | T細胞阻害タンパク質を伴うおよび伴わない、aprilおよびbaff阻害免疫調節タンパク質、ならびにその使用方法 |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
AU560472B2 (en) | 1981-08-25 | 1987-04-09 | Celltech Limited | Yeast expression vectors |
US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US4486533A (en) | 1982-09-02 | 1984-12-04 | St. Louis University | Filamentous fungi functional replicating extrachromosomal element |
US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
US4977092A (en) | 1985-06-26 | 1990-12-11 | Amgen | Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
US4661454A (en) | 1983-02-28 | 1987-04-28 | Collaborative Research, Inc. | GAL1 yeast promoter linked to non galactokinase gene |
US5139936A (en) | 1983-02-28 | 1992-08-18 | Collaborative Research, Inc. | Use of the GAL1 yeast promoter |
US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
CA1280080C (en) | 1984-12-06 | 1991-02-12 | Jacques Oberto | Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides |
US4751181A (en) | 1984-12-31 | 1988-06-14 | Duke University | Methods and compositions useful in the diagnosis and treatment of autoimmune diseases |
GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5063154A (en) | 1987-06-24 | 1991-11-05 | Whitehead Institute For Biomedical Research | Pheromone - inducible yeast promoter |
US5637677A (en) | 1987-07-16 | 1997-06-10 | The Trustees Of The University Of Pennsylvania | Biologically active compounds and methods of constructing and using the same |
DE721983T1 (de) | 1988-01-22 | 2002-07-04 | Zymogenetics, Inc. | Verfahren zur herstellung von biologisch-aktive Dimerpeptiden |
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5162228A (en) | 1988-12-28 | 1992-11-10 | Takeda Chemical Industries, Ltd. | Gylceraldehyde-3-phosphate dehydrogenase gene and promoter |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5162222A (en) | 1989-07-07 | 1992-11-10 | Guarino Linda A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses |
EP0438803B1 (en) | 1990-01-26 | 1997-03-12 | Immunomedics, Inc. | Vaccines against cancer and infectious diseases |
JPH05504479A (ja) | 1990-02-09 | 1993-07-15 | ザ ソーク インスティテュート フォア バイオロジカル スタディーズ | レチノイドレセプター組成物および方法 |
US5208146A (en) | 1990-11-05 | 1993-05-04 | The Regents Of The University Of California | Murine monoclonal anti-idiotype antibodies |
WO1994006463A1 (en) | 1992-09-14 | 1994-03-31 | Pfizer Inc | Immortalized cells and uses therefor |
WO1994009137A1 (en) | 1992-10-15 | 1994-04-28 | Genentech, Inc. | Antibodies against type 2 tumor necrosis factor receptor |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US5650550A (en) | 1993-10-01 | 1997-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant mice having a deficit of functional estrogen receptors |
US5523227A (en) | 1994-06-17 | 1996-06-04 | The Board Of Trustees Of The Leland Stanford Junior Univ. | DNA encoding calcium-signal modulating cyclophilin ligand |
JP3787355B2 (ja) | 1994-12-15 | 2006-06-21 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | Fas/apo1受容体機能のモジュレーター |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
DE19533447C1 (de) | 1995-09-09 | 1996-12-05 | Bbs Kraftfahrzeugtechnik | Verfahren und Vorrichtung zum Befüllen eines Gießwerkzeugs mit einer Metallschmelze |
US5716808A (en) | 1995-11-09 | 1998-02-10 | Zymogenetics, Inc. | Genetic engineering of pichia methanolica |
CA2237120C (en) | 1995-11-09 | 2005-03-01 | Zymogenetics, Inc. | Compositions and methods for producing heterologous polypeptides in pichia methanolica |
ES2210354T3 (es) | 1996-03-14 | 2004-07-01 | Human Genome Sciences, Inc. | Factor de necrosis tumoral humano delta y epsilon. |
AU718510B2 (en) | 1996-07-17 | 2000-04-13 | Zymogenetics Inc. | Transformation of pichia methanolica |
US5736383A (en) | 1996-08-26 | 1998-04-07 | Zymogenetics, Inc. | Preparation of Pichia methanolica auxotrophic mutants |
AU708572B2 (en) | 1996-07-17 | 1999-08-05 | Zymogenetics Inc. | Preparation of (pichia methanolica) auxotrophic mutants |
US6689579B1 (en) | 1996-10-25 | 2004-02-10 | Human Genome Sciences, Inc. | Polynucleotides encoding neutrokine-α |
EP2230307A1 (en) | 1996-10-25 | 2010-09-22 | Human Genome Sciences, Inc. | Neutrokine alpha |
AU5705898A (en) | 1996-12-17 | 1998-07-15 | Schering Corporation | Mammalian cell surface antigens; related reagents |
US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
CA2232743A1 (en) | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | A tnf homologue, tl5 |
JP2002504818A (ja) | 1997-06-06 | 2002-02-12 | リジェネロン ファーマシューティカルズ,インコーポレイテッド | リガンドファミリーのntn−2メンバー |
CA2292835A1 (en) | 1997-06-06 | 1998-12-10 | Regeneron Pharmaceuticals, Inc. | Ntn-2 member of tnf ligand family |
WO1999004001A1 (en) | 1997-07-21 | 1999-01-28 | Zymogenetics, Inc. | Tumor necrosis factor receptor ztnfr-5 |
US6015801A (en) | 1997-07-22 | 2000-01-18 | Merck & Co., Inc. | Method for inhibiting bone resorption |
AU9376498A (en) | 1997-09-05 | 1999-03-22 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
EP1012270A2 (en) | 1997-09-12 | 2000-06-28 | Apotech R&D S.A. | Kay - a novel immune system protein |
CA2303615A1 (en) | 1997-09-12 | 1999-03-18 | Jurg Tschopp | April- a novel protein with growth effects |
DE19831987A1 (de) | 1998-07-16 | 2000-01-20 | Bayer Ag | Diphenylimidazoline |
GB9828628D0 (en) | 1998-12-23 | 1999-02-17 | Glaxo Group Ltd | Novel ligand |
DE69938256D1 (xx) | 1998-12-30 | 2008-04-10 | Oligos Etc Inc | |
US20060067933A1 (en) | 1999-01-07 | 2006-03-30 | Gross Jane A | Soluble receptor BR43x2 and methods of using |
PT1141274E (pt) * | 1999-01-07 | 2004-02-27 | Zymogenetics Inc | Receptor soluvel br43x2 e metodos para sua utilizacao |
US7833529B1 (en) * | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
NZ513284A (en) | 1999-01-25 | 2003-10-31 | Biogen Inc | BAFF blocking agents and their use in the stimulation and inhibition of B-cells and immunoglobulins in immune responses |
JP2003526330A (ja) | 1999-02-23 | 2003-09-09 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | ニュートロカイン−αおよびニュートロカイン−αスプライス改変体 |
CA2366785C (en) | 1999-04-19 | 2012-02-07 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
US20030022233A1 (en) | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
WO2000073481A1 (en) | 1999-05-28 | 2000-12-07 | Targeted Genetics Corporation | Methods and compositions for lowering the level of tumor necrosis factor (tnf) in the tnf-associated disorders |
KR100897082B1 (ko) | 1999-08-17 | 2009-05-14 | 바이오겐 아이덱 엠에이 인코포레이티드 | Baff 수용체(bcma), 면역조절제 |
UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
PT1255558E (pt) * | 2000-02-16 | 2006-11-30 | Genentech Inc | Anticorpos anti-april e células hibridoma |
AU2006201471B2 (en) | 2000-02-16 | 2009-07-23 | Genentech, Inc. | Uses of agonists and antagonists to modulate activity of TNF-related molecules |
BR0110610A (pt) | 2000-04-11 | 2003-04-29 | Genentech Inc | Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos isolados |
US20040013674A1 (en) | 2001-04-27 | 2004-01-22 | Christine Ambrose | Taci as an anti-tumor agent |
SI1297013T1 (sl) | 2000-04-27 | 2007-06-30 | Biogen Idec Inc | Uporaba TACI kot protitumorskega sredstva |
CA2408617A1 (en) | 2000-05-12 | 2001-11-22 | Amgen Inc. | Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
ES2398203T3 (es) | 2000-08-11 | 2013-03-14 | Kyowa Hakko Kirin Co., Ltd. | Polipéptido que regula el metabolismo del fosfato, el metabolismo del calcio, el metabolismo de la calcificación y de la vitamina D y ADN que codifican el mismo |
JP2004516826A (ja) | 2000-11-07 | 2004-06-10 | ザイモジェネティクス,インコーポレイティド | ヒト腫瘍壊死因子受容体 |
ES2379977T3 (es) * | 2001-05-24 | 2012-05-07 | Zymogenetics, Inc. | Proteínas de fusión de taci-inmunoglobulina |
WO2003014294A2 (en) | 2001-08-03 | 2003-02-20 | Genentech, Inc. | Tacis and br3 polypeptides and uses thereof |
US20050163775A1 (en) | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
EP1675609A1 (en) | 2003-10-20 | 2006-07-05 | Biogen Idec MA Inc. | Therapeutic regimens for baff antagonists |
AR059945A1 (es) | 2005-08-09 | 2008-05-14 | Zymogenetics Inc | Metodos para tratar afecciones malignas de celulas b que utilizan una molecula de fusion taci-ig |
AR059025A1 (es) | 2005-08-09 | 2008-03-12 | Zymogenetics Inc | Metodos para el tratamiento y prevencion de proliferacion de celulas anormales utilizando moleculas de fusion taci |
-
2006
- 2006-08-09 AR ARP060103488A patent/AR059945A1/es unknown
- 2006-08-09 UA UAA200802950A patent/UA93516C2/ru unknown
- 2006-08-09 CA CA002618765A patent/CA2618765A1/en not_active Abandoned
- 2006-08-09 ZA ZA200801354A patent/ZA200801354B/xx unknown
- 2006-08-09 EP EP06801193A patent/EP1922080A2/en not_active Withdrawn
- 2006-08-09 US US11/502,134 patent/US7842292B2/en not_active Expired - Fee Related
- 2006-08-09 EA EA200800560A patent/EA016083B1/ru not_active IP Right Cessation
- 2006-08-09 JP JP2008526212A patent/JP2009507777A/ja active Pending
- 2006-08-09 MX MX2008001661A patent/MX2008001661A/es active IP Right Grant
- 2006-08-09 AU AU2006278229A patent/AU2006278229B2/en not_active Ceased
- 2006-08-09 CN CNA2006800296288A patent/CN101262876A/zh active Pending
- 2006-08-09 WO PCT/US2006/031277 patent/WO2007019575A2/en active Application Filing
- 2006-08-09 KR KR1020087005714A patent/KR20080056714A/ko not_active Application Discontinuation
-
2007
- 2007-12-25 IL IL188403A patent/IL188403A/en not_active IP Right Cessation
-
2008
- 2008-03-04 NO NO20081149A patent/NO20081149L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US7842292B2 (en) | 2010-11-30 |
WO2007019575A3 (en) | 2007-06-21 |
IL188403A0 (en) | 2008-08-07 |
ZA200801354B (en) | 2009-08-26 |
KR20080056714A (ko) | 2008-06-23 |
IL188403A (en) | 2011-06-30 |
JP2009507777A (ja) | 2009-02-26 |
EA200800560A1 (ru) | 2008-06-30 |
EA016083B1 (ru) | 2012-02-28 |
WO2007019575A2 (en) | 2007-02-15 |
AU2006278229B2 (en) | 2011-10-27 |
CA2618765A1 (en) | 2007-02-15 |
CN101262876A (zh) | 2008-09-10 |
MX2008001661A (es) | 2008-04-07 |
EP1922080A2 (en) | 2008-05-21 |
US20070071760A1 (en) | 2007-03-29 |
UA93516C2 (ru) | 2011-02-25 |
AU2006278229A1 (en) | 2007-02-15 |
AR059945A1 (es) | 2008-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20081149L (no) | Fremgangsmate for behandling av B-celle-maligniteter ved bruk av TACI-IG fusjonsmolekyl | |
NO20045056L (no) | Fremgangsmater for behandling av hepatitt | |
MX349188B (es) | Sns - 595 y metodos para utilizar el mismo. | |
ATE360631T1 (de) | Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors | |
GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
ATE449604T1 (de) | Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren | |
CY1111050T1 (el) | Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων | |
DK1638586T3 (da) | Synergistisk sammensætning til behandling af diabetes mellitus | |
MX2007011545A (es) | Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr. | |
MX2007009649A (es) | Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer. | |
SG164368A1 (en) | Treatment of cancer | |
WO2005051429A3 (en) | Targeted conjugates with a modified saccharide linker | |
TW200639159A (en) | Treatment of pain | |
NO20064325L (no) | Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes | |
EA200700407A1 (ru) | Производные хиназолина и их использования при лечении тромбоцитемии | |
WO2004091540A3 (en) | Methods of treating pain and compositions for use therefor | |
ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
PL1654253T3 (pl) | Podstawione pochodne 3-pirolidynoindolu | |
MXPA05007462A (es) | Derivados de pirrolopiridazina. | |
EA201000630A1 (ru) | Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови | |
MX2007004955A (es) | Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente. | |
ATE466841T1 (de) | 1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden | |
DE602004017326D1 (de) | Tetrahydrocarbazolderivate und deren pharmazeutische verwendung | |
NO20081152L (no) | Metoder for behandling og forhindring av abnormal celleproliferering ved bruk av TACI-funsjonsmolekyler | |
GB0606015D0 (en) | therapeutic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |